BPC-157 5mg — Pilot Format HPLC ≥98% Purity

Zoom

20,00 €

Tax included • Free delivery from 99€

Almost sold out, alert me on restock

The 10mg is in stock, shipped on the next dispatch, at 33,00 €I take the 10mg

Worth knowing

This product contains BPC-157. Published work covers angiogenesis, the formation of new blood vessels. No randomised human clinical trial has characterised contraindications.

The theoretical alerts described in preclinical work concern a history of cancer, particularly vascularised solid tumours, pregnancy and breastfeeding, and proliferative retinopathies.

Our BPC-157 5 mg vial is the ideal entry format for researchers wishing to initiate a first exploratory protocol without committing to large stock. With 5 mg of lyophilized peptide per vial at HPLC purity ≥98 %, this format suits short research cycles (2 to 3 weeks) and preliminary validations before moving to a more extended format. The certificate of analysis is published on this page, viewable before you order. BPC-157 5 mg is intended for independent researchers, experimental sports medicine clinics, and laboratories prioritizing maximum supply flexibility. Why choose the 5 mg format? Reduced initial investment, reconstitution flexibility (1 ml = 5 mg/ml or 2 ml = 2.5 mg/ml for fine dosing), typical autonomy 2-3 weeks at 250 mcg/day. The perfect pilot format to document a first phase before escalation.

Science

01
Mechanism of action

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), derived from a body-protection sequence originally identified in human gastric juice. Its unusual stability in acidic environments sets it apart from conventional peptides: the literature has reported a meaningful half-life at pH 2 and resistance to digestive proteases, making it a unique subject of study within the regenerative research peptide class.

At the molecular level, preclinical models have suggested a multimodal mechanism. BPC-157 modulates the nitric oxide (NO) system via an eNOS / neuronal NOS axis, which according to published observations influences local vasodilation and tissue perfusion. Complementary work has documented activation of the VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) pathway, involved in angiogenesis, along with upregulation of early growth response genes (Egr-1) and the FAK-paxillin transcription factor in studied endothelial cells.

The peptide has also been reported to interact with central dopaminergic and serotonergic axes: rodent behavioral studies describe effects on neuroplasticity, GABAergic tone, and stress response. On the gastrointestinal front, literature has described mucosal barrier protection via modulation of endogenous prostaglandin (PGE2) and heat shock proteins (HSP70/90). These converging mechanisms position BPC-157 as a research peptide of particular interest in tissue-repair models (tendons, ligaments, skeletal muscle), traumatic brain injury (TBI) models, and experimental gastropathy.

It is critical to recall that all of this data comes from preclinical models (rodent, porcine, in vitro) and limited case studies. No marketing authorization exists for therapeutic human use: BPC-157 remains strictly a peptide for exploratory research.

Structurally, BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, mass 1419.6 Da) derived from a protective sequence identified by Sikiric and colleagues (University of Zagreb) from a stable fragment of human gastric juice, pepsin-resistant (Sikirić et al., em">Eur J Pharmacol 1991, J Physiol Paris 1997). Its stability in gastric acid radically distinguishes BPC-157 from most naturally occurring proteolysis-sensitive peptides. Molecular pathways documented in preclinical research include: (1) activation of nitric oxide (NO) synthesis via L-arginine/eNOS pathway, (2) transcriptional upregulation of VEGF-A and FGF-2 favouring angiogenesis, (3) modulation of the Egr-1 early transcription factor involved in fibroblast proliferation, (4) interaction with 5-HT2A and dopaminergic receptors in some behavioural models, (5) stabilisation of endothelial function via eNOS modulation and reduction of oxidative stress (8-OH-dG, MDA).

Clinical data

02Clinical studies

The BPC-157 preclinical corpus is dense and spans over two decades, driven primarily by the Sikiric group (Zagreb University School of Medicine). The main publications cover several converging experimental models.

Sikiric et al. (Journal of Physiology — Paris, 2001; DOI 10.1016/S0928-4257(01)00003-5) laid the initial mechanistic foundation, documenting gastric cytoprotection and mucosal barrier restoration in rats subjected to various chemical stressors (ethanol, NSAIDs, caustic agents). This foundational work was extended in Current Pharmaceutical Design (Sikiric et al. 2011; DOI 10.2174/138161211795589837), which synthesizes over 50 distinct animal models and positions BPC-157 as a "stable gastric pentadecapeptide" candidate.

On tendon repair, Staresinic et al. (Journal of Orthopaedic Research 2003; DOI 10.1016/S0736-0266(03)00016-X) reported in rats an acceleration of Achilles tendon healing after transection, with improved histological and biomechanical parameters versus control. Chang et al. (Journal of Applied Physiology 2011; DOI 10.1152/japplphysiol.00110.2011) extended these observations to the ischemia-reperfusion-injured quadriceps tendon.

In the cerebral field, Klicek et al. (Journal of Physiology and Pharmacology 2013) documented attenuation of post-traumatic lesions in a murine TBI model, with preservation of motor parameters assessed via neurological scale. Complementary work on MPTP neurotoxicity suggested a protective action on the nigrostriatal dopaminergic system.

On the cardiovascular side, Sikiric et al. (European Journal of Pharmacology 2016) reported effects on experimentally induced pulmonary hypertension and on ventricular arrhythmia in rats. Finally, colitis models (DSS-induced ulcerative colitis in mice) have documented restoration of intestinal mucosal integrity.

Critical limitations of the corpus: the vast majority of data comes from a limited number of laboratories, independent reproducibility studies are rare, and no large-scale randomized controlled phase 3 human clinical trial has been published or registered. BPC-157 remains in a regulatory gray zone and is strictly a preclinical research tool.

The rodent preclinical models documented for BPC-157 cover an exceptionally broad spectrum. In experimental orthopaedics: transected rat Achilles tendon (Staresinic 2003, Chang 2011), patellar tendon, lateral knee ligament, medial collateral ligament, rotator cuff tendon — restoration of collagenic fascicular organisation on histology and mechanical tension strength at 4-6 weeks. In experimental gastroenterology: gastric ulcers induced by ethanol, aspirin, indomethacin, duodenal cysteamine — ulcer index reduction of 60-90% depending on models. In experimental IBD: TNBS-induced colitis, DSS in C57BL/6J mice — decrease in histopathological scores and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). In experimental orthodontics: ligature-induced periodontitis, cuneiform bone fractures, rat calvaria defects. In cardiovascular: aortic aneurysm models, hepatic ischaemia-reperfusion, deep vein thrombosis. In neurology: closed head trauma, spinal cord hemisection, hepatic encephalopathy. All these studies are preclinical; no validated clinical data in humans is available for therapeutic use.

1
Gastro-intestinalStable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. · Current Pharmaceutical Design · 2011
2
TendonThe promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH · Journal of Applied Physiology · 2011
3
AngiogenèseBPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing
Seiwerth S, Brcic L, Vuletic LB, et al. · Current Pharmaceutical Design · 2018
4
Tissu mouGastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Gwyer D, Wragg NM, Wilson SL · Cell and Tissue Research · 2019

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Recommended reconstitution: 1 ml bacteriostatic water for injection → final concentration 5 mg/ml. Alternative volume: 2 ml (2.5 mg/ml, for finer dosing). Procedure: 1) let the vial and diluent reach room temperature (15 minutes); 2) disinfect the vial stopper with 70% alcohol; 3) draw bacteriostatic water into a sterile syringe; 4) inject slowly along the inner wall of the vial; 5) gently swirl the vial until complete dissolution — never shake vigorously. Dosages reported in preclinical literature: documented human research protocols (outside authorized therapeutic framework) typically mention 250-500 mcg per day subcutaneously. At 5 mg/ml concentration, 250 mcg = 0.05 ml (5 units on 100 IU syringe) and 500 mcg = 0.1 ml (10 units). Autonomy: 5 mg allows approximately 20 days at 250 mcg/day, or 10 days at 500 mcg/day — ideal format for a 2- to 3-week pilot cycle. Post-reconstitution storage: refrigerator 2-8 degrees Celsius, 28-day usage window with bacteriostatic. On a short pilot cycle, the vial can be fully used well before the stability limit.

Reconstitution for this format (5 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
1 ml	5 mg/ml	40 UI = 2 mg
2 ml	2,5 mg/ml	40 UI = 1 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Lyophilized unreconstituted BPC-157 can be stored for up to 24 months at -20 degrees Celsius in its original sealed packaging, protected from light and humidity. At refrigerated temperature (2-8 degrees Celsius), documented stability covers at least 12 months. At room temperature (below 25 degrees Celsius), the recommended duration for temporary transport or storage does not exceed 4 weeks. Once reconstituted with bacteriostatic water for injection, BPC-157 must imperatively be stored between 2 and 8 degrees Celsius. Post-reconstitution stability is documented in the literature for up to 28 days when bacteriostatic water (containing 0.9% benzyl alcohol) is used. With preservative-free sterile water, the usage window narrows to 5-7 days. The peptide is particularly sensitive to several deleterious factors: repeated freeze-thaw cycles (prefer aliquots for large volumes), direct UV light exposure, abrupt thermal variations, and contact with non-inert metallic surfaces. Freeze-thaw cycles should be limited to a maximum of three. The certificate of analysis is published on this page, viewable before you order. Optimal pH lies between 5.5 and 7.0: avoid any reconstitution in acidic (pH < 4) or basic (pH > 9) solution which would favour hydrolytic degradation of proline-proline bonds. Never refreeze an already-reconstituted solution: freeze/thaw cycles generate aggregates detectable by SEC-HPLC and decrease biological activity in rodent models. Packaging in type I borosilicate glass vial with siliconised butyl stopper limits peptide/container interactions and guarantees batch integrity for planned study duration.

01Is BPC-157 5 mg enough for a complete research cycle?

The 5 mg format covers approximately 20 days of protocol at typical 250 mcg/day dose, or 10 days at 500 mcg/day. It is perfectly suited for short exploratory cycles, initial titration phases, or researchers wishing to document a first response before committing to a more extended format. For cycles longer than 3 weeks or combined protocols, the 10 mg format offers a better volume/price ratio and extended autonomy.

02How do I reconstitute BPC-157 5 mg to obtain 5 mg/ml?

Inject 1 ml bacteriostatic water into the 5 mg vial: 5 mg / 1 ml = 5 mg/ml. With a 100 IU insulin syringe, 250 mcg corresponds to 5 units and 500 mcg to 10 units. Diluent injected along the inner wall (never onto the lyophilisate), gentle rotation until complete dissolution, never vigorous shaking. Post-reconstitution storage: 2-8 degrees Celsius, 28-day window with bacteriostatic.

03Why is BPC-157 considered stable in acidic environments?

The BPC-157 peptide sequence contains several proline residues (three consecutive prolines at positions 3-4-5) that rigidify the three-dimensional structure and limit enzymatic hydrolysis. Literature has documented a meaningful half-life at pH 2 and increased resistance to digestive proteases, which radically distinguishes BPC-157 from conventional peptides that are degraded within minutes in the stomach.

04Can BPC-157 be combined with TB-500 in research?

Research protocols frequently combine BPC-157 and TB-500 because the two peptides act on distinct but complementary molecular pathways: BPC-157 via VEGFR2 and the NO pathway (local angiogenesis), TB-500 via G-actin sequestration and cell mobilization. Preclinical tendon repair models have reported potential synergy, although no controlled human clinical study has been published. The combination remains strictly a subject of scientific investigation.

05Which biological markers are studied in BPC-157 protocols?

Preclinical protocols typically track inflammatory markers (CRP, IL-6, TNF-alpha), hepatic parameters (ALT, AST, GGT), complete blood count, angiogenesis markers (serum VEGF, Egr-1), blood pressure and, depending on the model, histological markers (type I and III collagen, vascular density) and biomechanical parameters (tendon tensile strength). No validated human standard exists since this is not an authorized therapeutic use.

06Is your BPC-157 authentic and research-grade?

BPC-157 is synthesized by solid-phase peptide synthesis (SPPS) with HPLC purity at least 98%. The certificate of analysis is published on this page, viewable before you order.

07What is the delivery lead time in Europe?

Order today, shipped the next day: dispatch Monday to Saturday from our stock in France, with real-time tracking from dispatch. Allow 2 to 5 business days in France, 3 to 5 to Belgium, Luxembourg, Germany and the Netherlands, 4 to 7 to the rest of the EU. No customs within the EU, free shipping from €99 in France and from €150 in the EU.

08What is the documented tolerance profile in preclinical studies?

Preclinical rodent studies have reported a particularly favorable tolerance profile, with a very high LD50 and no major systemic side effects at studied therapeutic doses. Rare observations concern local injection site reactions (transient erythema). These data cannot, however, be extrapolated to humans: no regulatory human toxicological study (standard phase 1) has been conducted. BPC-157 remains exclusively a research peptide, not intended for human use.

09Is BPC-157 stable at room temperature?

In lyophilised form, BPC-157 tolerates short excursions at room temperature (< 72h) with no purity loss detectable by RP-HPLC. For long-term storage (> 1 week), prefer -20°C under desiccation. Reconstituted in bacteriostatic water, solution stays stable 28 days at 2-8°C. Absolutely avoid direct UV exposure (Trp/Tyr photolytic degradation).

10What HPLC purity is expected for a research-grade BPC-157 batch?

A research-grade (RUO) batch must show RP-HPLC purity ≥ 98% on two orthogonal gradients (typically ACN/H2O/0.1% TFA and MeOH/H2O/0.1% FA), mass confirmation by ESI-HRMS (± 1 ppm vs theoretical 1419.55 Da), identity by amino acid analysis post-6N HCl hydrolysis 110°C 24h, and LAL assay < 0.25 EU/mg. The certificate of analysis is published on this page, viewable before you order.

11Does BPC-157 require reconstitution with specific bacteriostatic water?

For SC/IP/IM injectable animal research protocols, recommended reconstitution is in bacteriostatic water (0.9% benzyl alcohol) ensuring microbiological preservation of solution over 28 days at 2-8°C. Sterile water for injection is acceptable for one-off use < 24h. Avoid hypertonic saline solutions or high-phosphate buffers which can precipitate the peptide at high concentration (> 5 mg/mL).

Benchmark

Similar peptides

BPC-157 occupies a unique position within the regenerative research peptide class. Unlike TB-500 (Thymosin Beta-4 fragment), which acts primarily via G-actin sequestration and endothelial progenitor cell mobilization, BPC-157 exerts its action via an NO-dependent pathway and VEGFR2 modulation — two distinct but potentially complementary mechanisms, which is why research protocols sometimes combine both peptides (synergy documented in animal tendon repair models).

Compared to classical growth factors such as IGF-1 or GH (Growth Hormone), BPC-157 is distinguished by its local specificity and absence of marked endocrine systemic effects in studied models. GH and IGF-1 operate via generalized anabolic stimulation and mitogenesis, whereas BPC-157 appears to favor modulation of the tissue microenvironment (local angiogenesis, controlled inflammation, endothelial stabilization).

Compared to anti-inflammatory peptides such as LL-37 or cathelicidins, BPC-157 does not display direct antimicrobial activity but modulates the immune-vascular axis in a more refined manner. Compared to classical gastroprotective peptides such as sucralfate or proton pump inhibitors (PPIs), it acts via a completely different pathway: restoration of mucosal microcirculation rather than acid reduction or formation of a mechanical protective layer.

In our shop, BPC-157 is the most ordered recovery peptide, and one of the most documented in preclinical literature. Commercialization for human therapeutic use remains prohibited in France, Europe, and the United States, hence the importance of sourcing strictly intended for in vitro and ex vivo research.

Compared to other regenerative research peptides, BPC-157 sits in a specific segment: multi-organ systemic action with exceptional acid stability and versatility (documented PO, IP, SC, IM). TB-500 (synthetic thymosin β-4 fragment, LKKTETQ, 889 Da) shares tissue-healing indications but acts through a different mechanism (G-actin sequestration, Ac-SDKP anti-fibrosis). The BPC-157 + TB-500 combination is proposed in grey literature as complementary in preclinical tendon protocols. Compared to GHK-Cu (340 Da tripeptide), BPC-157 preferentially targets deep tissues and visceral healing, while GHK-Cu focuses on skin and dermal collagen production. Compared to PRP (platelet-rich plasma), BPC-157 offers the advantage of a standardised precisely-dosed formulation, unlike autologous PRP inherent variability. Compared to IGF-1 LR3, BPC-157 does not directly stimulate cell proliferation via IGF-1R but acts indirectly via NO/VEGF pathways — distinct use profile.

BPC-157 5mg Recovery

Regeneration

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Regeneration

Product information

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents